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Abstract
Background: Several investigations are currently available to establish the diagnosis of coronary heart disease
(CHD). Of these, cardiovascular magnetic resonance (CMR) offers the greatest information from a single test,
allowing the assessment of myocardial function, perfusion, viability and coronary artery anatomy. However, data
from large scale studies that prospectively evaluate the diagnostic accuracy of multi-parametric CMR for the
detection of CHD in unselected populations are lacking, and there are few data on the performance of CMR
compared with current diagnostic tests, its prognostic value and cost-effectiveness.
Methods/design: This is a prospective diagnostic accuracy cohort study of 750 patients referred to a
cardiologist with suspected CHD. Exercise tolerance testing (ETT) will be preformed if patients are physically
able. Recruited patients will then undergo CMR and single photon emission tomography (SPECT) followed in all
patients by invasive X-ray coronary angiography. The order of the CMR and SPECT tests will be randomised. The
CMR study will comprise rest and adenosine stress perfusion, cine imaging, late gadolinium enhancement and
whole-heart MR coronary angiography. SPECT will use a gated stress/rest protocol. The primary objective of the
study is to determine the diagnostic accuracy of CMR in detecting significant coronary stenosis, as defined by X-
ray coronary angiography. Secondary objectives include an assessment of the prognostic value of CMR imaging, a
comparison of its diagnostic accuracy against SPECT and ETT, and an assessment of cost-effectiveness.
Discussion: The CE-MARC study is a prospective, diagnostic accuracy cohort study of 750 patients assessing the
performance of a multi-parametric CMR study in detecting CHD using invasive X-ray coronary angiography as
the reference standard and comparing it with ETT and SPECT.
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Coronary heart disease (CHD) is a major cause of morbid-
ity and mortality in the UK, affecting approximately 2.6
million people [1]. In a typical hospital setting, a variety
of investigations may be used to diagnose CHD, risk strat-
ify patients and plan their clinical management. The high-
est risk patients may proceed directly to X-ray coronary
angiography, but the vast majority of patients at low to
intermediate risk undergo non-invasive assessment in the
form of exercise tolerance testing (ETT), stress echocardi-
ography or single photon emission computed tomogra-
phy (SPECT), in order to identify those most likely to
require coronary revascularisation. The diagnostic process
commonly involves a multiple-test strategy, either due to
limitations in the performance of any individual test (e.g.
~30% of patients may be physically unable to perform an
adequate ETT) or limitations in the test's diagnostic accu-
racy. For example, the reported sensitivity and specificity
of ETT for angiography-proven CHD was 68% and 77%
respectively from a large meta-analysis where the preva-
lence of CHD was high at over 60% [2]. SPECT provides
greater diagnostic accuracy than ETT, 86% and 74% sensi-
tivity and specificity respectively, compared to X-ray angi-
ography for the diagnosis of CHD [3], being typically
performed in patients with equivocal ETT results, those
who cannot exercise or those who have fixed resting ECG
abnormalities such as left bundle branch block [3].
The need for a reliable screening tool to select patients for
invasive X-ray coronary angiography stems from the risks
associated with exposure to ionising radiation and the
small but significant morbidity and mortality associated
with the procedure (0.11% risk of procedural death,
0.05% myocardial infarction, 0.07% stroke) [4]. The issue
of radiation is often overlooked, but the risk of developing
a solid tumour has been estimated at 1 in 2500 diagnostic
coronary angiographic procedures [5,6]. In 2006, approx-
imately 216,000 X-ray coronary angiograms, 74,000 per-
cutaneous coronary interventions [7] and 20,000
coronary artery bypass graft operations were performed in
the UK [8]. It is therefore evident that a significant propor-
tion of patients undergoing coronary angiography do not
subsequently require revascularisation and hence the X-
ray coronary angiogram is performed only for diagnostic
purposes. Cardiac Magnetic Resonance (CMR) might reli-
ably identify those patients who actually require revascu-
larisation and thereby reduce the need for unnecessary
invasive investigation in the remainder.
CMR imaging
CMR is the most accurate and reproducible technique for
morphological imaging of the heart because of its out-
standing image resolution and tissue contrast. In addition
to providing detailed anatomical information, CMR can
assess myocardial function, perfusion, tissue viability, cor-
onary artery anatomy and coronary blood flow with accu-
racy similar or superior to that provided by other
established tests (Fig. 1) [9-16]. Furthermore, CMR is safe,
non-invasive and does not expose patients to ionising
radiation.
A major strength of CMR is that ventricular function, tis-
sue viability, myocardial perfusion and coronary anatomy
can be assessed in a single comprehensive study [15,16].
To obtain equivalent information by current clinically val-
idated techniques would require a combination of
echocardiography, ETT and/or SPECT as well as invasive
or CT coronary angiography. CMR may therefore more
accurately and more cost effectively identify those patients
with suspected CHD who require coronary revascularisa-
tion than the current 'battery of tests'. It has been shown
that combining the four components function, viability,
perfusion and coronary anatomy into a single CMR exam-
ination improves the sensitivity for the diagnosis of signif-
icant CHD over and above that for any individual
component, with a combined sensitivity and specificity
for the comprehensive analysis of 96% and 83% respec-
tively [16]. These findings have been corroborated by a
recent study by Klem et al, which found the combination
of CMR perfusion and late gadolinium enhancement
CMR to be superior in detecting coronary artery disease
than CMR perfusion alone [17].
The recent MR-IMPACT study was the first multi-centre
study comparing the diagnostic ability of CMR and of
SPECT in comparison with X-ray angiography in 241
patients and showed equal performance of the two tests
[18]. An important limitation of this and previous CMR
publications as well as most of the SPECT literature, is that
the recruited patients were already listed for coronary ang-
iography or that analysis was retrospective, introducing an
important selection bias into these studies.
Aims and objectives
The primary objective of this study is to assess the diag-
nostic accuracy of CMR in detecting significant CHD com-
pared to the current 'reference standard' X-ray
angiography. Secondary objectives will be to a) compare
the diagnostic accuracy of CMR in detecting significant
CHD against the current standard clinical investigations
of ETT and SPECT; b) assess the prognostic value of CMR
in predicting time to a major adverse cardiovascular event
and c) to evaluate the cost effectiveness of CMR in a diag-
nostic strategy for the systematic investigation of patients
with suspected CHD.
Methods
Study design
This is a prospective, diagnostic accuracy cohort study of
patients referred to cardiologists for the further evaluation
of symptoms thought to be angina pectoris. All recruited
patients will undergo SPECT, CMR, ETT (when physicallyPage 2 of 9
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Patients will be recruited from Leeds Teaching Hospitals
NHS Trust, Leeds, UK and Pinderfields Hospital, Wake-
field, UK. All SPECT and CMR scans will be undertaken at
Leeds General Infirmary. The study will be performed in
accordance with the Declaration of Helsinki (October
2000), with all patients providing informed written con-
sent. The study protocol and other relevant documenta-
tion has been approved by the Leeds (West) Research
Ethics Committee (REC). Patients will then be ran-
domised, via an automated 24-hour randomisation sys-
tem, to the order in which they undergo SPECT and CMR
imaging. Stratified permuted block randomisation will be
used to ensure that the groups are well balanced for age
(<65, ≥65) and gender. Finally all patients will undergo X-
ray coronary angiography, regardless of the treating physi-
cian's chosen clinical pathway, within 4 weeks of ran-
domisation, which will act as the reference standard.
Statistical analyses will be carried out by the Clinical Trials
Research Unit (CTRU), University of Leeds, UK and the
Centre for Health Economics, University of York, UK. The
study population will be followed up prospectively for a
minimum of 3 years to establish the prognostic value of
CMR in predicting long-term major cardiovascular events.
Eligibility
Inclusion criteria for the study are stable symptoms
thought to be angina pectoris, at least one cardiovascular
risk factor (smoking, family history of premature cardio-
vascular disease, arterial hypertension, hyperlipidaemia,
diabetes mellitus), body weight less than 110 kg, suitabil-
ity for coronary revascularisation if required and sinus
rhythm.
Exclusion criteria for the study are previous coronary artery
bypass surgery (but not percutaneous coronary interven-
tion), evidence of crescendo angina or acute coronary syn-
drome, contraindication to CMR imaging (e.g. pacemaker,
intra-orbital metallic debris, intracranial clips) or adenosine
infusion (regular adenosine antagonist medication, reversi-
ble airways disease, second or third degree atrio-ventricular
heart block, sino-atrial disease), pregnancy, known adverse
reaction to Gadolinium-based contrast agents, inability to lie
supine for 60 minutes and chronic renal failure (estimated
glomerular filtration rate ≤ 30 ml/min).
Recruitment and data collection
Patients will be identified from consecutive referrals to
rapid access chest pain and general cardiology clinics in
the Leeds and Wakefield area, which has a combined pop-
ulation of approximately one million people. Patients will
be reviewed by a clinician and will have an ETT if they are
physically able. Patients who are deemed suitable and
who are proceeding for further investigations will be
offered the chance to participate in the study.
An anonymised log of all patients screened for eligibility
who are not recruited either because they are ineligible or
because they decline participation will be kept. If a patient
is enrolled in the study, information on risk factors
including age, gender, cholesterol, blood pressure, smok-
ing and diabetes, will be collected. After enrolment, the
treating clinician will be asked to make a provisional diag-
nosis (definite angina, probable angina, possible angina
or atypical symptoms) and indicate what their planned
sequence of investigations (with options of ETT, SPECT
and X-ray angiography or none) for this individual patient
would have been, had they not participated in the study.
This clinical intention record will allow assessment as to
whether the use of CMR, or SPECT, impacts on the out-
come for individual patients. It will not affect the study
investigations and every patient will undergo all three
study investigations in the order prescribed for the study.
Investigation details
CMR
CMR studies will be carried out on a dedicated cardiac
research scanner (1.5 Tesla Intera CV, Philips, Best, The
Netherlands) equipped with 'Master' gradients (30 mT/m
peak gradients and 150 mT/m/ms slew rate) based at the
Leeds General Infirmary, Leeds, UK. The CMR signals are
Sample cardiac MR imagesFigur  1
Sample cardiac MR images. A) Standard four chamber 
SSFP view of the heart LV showing both atria and ventricles. 
B) Vertical long axis late gadolinium enhancement view of the 
LV showing infarction of the anteroapical wall (arrow). C) 
Short axis view of the LV showing a perfusion defect in the 
inferior wall (arrow). D) Typical MR angiogram of a right cor-
onary artery.Page 3 of 9
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ECG gating and triggering will be performed by the vector-
cardiographic method. The total scan duration is approx-
imately one hour and will comprise (Fig. 2):
1. Low resolution survey and sensitivity encoding
(SENSE) reference scans performed prior to the cardiac
localiser scans which define short axis, vertical long axis
and horizontal long axis acquired with a balanced steady
state free precession (SSFP), single slice, breath-hold pulse
sequence. Pulse sequence parameters: echo time (TE) 1.6
ms, repetition time (TR) 3.2 ms, slice thickness 8 mm,
matrix 192 × 192, field of view 320–400 mm according to
patient size, SENSE factor 1.7 to 2.0, 30–50 phases per car-
diac cycle.
2. Stress myocardial perfusion study. A T1-weighted satu-
ration-recovery segmented k-space gradient echo pulse
sequence combined with SENSE will be used to assess first
pass myocardial perfusion in 3 short axis slices, posi-
tioned according to the "3 of 5" technique [19]. Pulse
sequence parameters: TE 1.0 ms, TR 2.7 ms, flip angle 15°,
single saturation pre-pulse per R-R interval shared over
three slices, SENSE factor 2, matrix 144 × 144, field of
view 320–460 mm, slice thickness 10 mm. For stress per-
fusion imaging intravenous adenosine will be adminis-
tered at a dose of 140 μg/kg/min. The patient's blood
pressure will be recorded every two minutes and the heart
rhythm monitored on the vector-ECG. The perfusion
study will commence approximately 4 minutes into the
adenosine infusion. A bolus intravenous injection of 0.05
mmol/kg dimeglumine gadopentetate (Magnevist®,
Schering AG, West Sussex, UK) followed by a 15 ml saline
flush will be delivered through an arm vein at 5 ml/s using
a power injector (Spectris®, Medrad, Pittsburgh, Pennsyl-
vania), while the patient holds their breath in end-expira-
tion.
3. Coronary MR Angiography. A low-resolution coronary
survey scan will be performed during free breathing, using
a respiratory navigator. Timing of the diastolic coronary
rest period is estimated from the four-chamber free
breathing cine scan. Three dimensional, whole heart cor-
onary MR angiography is acquired using a balanced SSFP
sequence and a respiratory navigator to compensate for
respiratory motion during free breathing. Pulse sequence
parameters: TE 2.3 ms, TR 4.6 ms, flip angle 100°, T2 and
fat saturation pre-pulses, SENSE factor 1.7, duration of
acquisition up to 120 ms per R-R interval (determined by
length of diastolic rest period), matrix 304 × 304, field of
view 320–460 mm, slice thickness 0.9 mm, 100–120
slices as required.
4. Resting myocardial perfusion study. Pulse sequence,
slice positioning, and injection characteristics identical to
the stress perfusion scan.
5. Additional intravenous injection of dimeglumine gado-
pentetate (0.1 mmol/kg), given within 60 seconds of the
rest perfusion scan, in preparation for late gadolinium
enhanced CMR.
6. Resting wall-motion. Contiguous cine stack encom-
passing the entire left ventricle in 10–12 slices (depending
on left ventricular long axis length). Three additional
slices, with identical slice positioning to the perfusion
sequence will also be acquired. Pulse sequence parame-
ters: balanced SSFP, TE 1.7 ms, TR 3.5 ms, flip angle 60°,
SENSE factor 2, matrix 192 × 192, field of view 320–460
mm, slice thickness 10 mm, at least 20 phases per cardiac
cycle, 1–2 slices per breath-hold.
7. Late gadolinium enhanced CMR performed between 10
and 20 minutes after step 5. The optimal inversion time to
null signal from normal myocardium will be determined
using a modified Look-Locker approach [20]. Subse-
quently, a T1-weighted, segmented inversion-recovery
gradient echo sequence will be used to acquire a contigu-
ous stack of short axis slices covering the entire left ventri-
cle. Pulse sequence parameters: non-selective 180° pre-
pulse, TE 1.9 ms, TR 4.9 ms, flip angle 15°, inversion time
adjusted individually according to the Look-Locker scan,
10–12 short axis slices, single slice per breath-hold, matrix
240 × 240, field of view 320–460 mm as per patient size.
Further slices will be acquired in the vertical and horizon-
tal long axis orientations (at least one slice per orienta-
tion, more if clinically indicated.)
ETT
Exercise tolerance testing will be performed if the patient
is able to exercise appropriately. This will take place at the
recruiting hospital using standard Bruce protocol in most
cases, although alternate protocols can be used if
required. The following data will be recorded: Resting
heart rate and BP, peak exercise stress heart rate and exer-
cise duration, achievement of 85% age predicted heart
rate and total workload (Metabolic Equivalents, METS),
reason for test termination including reproduction of clin-
ical symptoms, degree of ST segment shift, presence of
arrhythmia and heart rate recovery at one minute.
SPECT
SPECT radionuclide imaging will be carried out a dedi-
cated cardiac gamma camera (MEDISO Cardio-C, Buda-
pest, Hungary) based at the Leeds General Infirmary,
Leeds, UK. Patients will undergo a two day scanning pro-
tocol using the radioisotope tracer 99mTc tetrofosmin
(Myoview), standard dose of 400 MBq for each examina-
tion, adjusted to weight to a maximum of 600 MBq per
examination. Stress and rest ECG gated SPECT images will
be acquired with the patients in the supine position with
a total of 64 projections, 3 degree interval, every 40 sec-
onds over a 180 degree orbit. At each projection 8 ECGPage 4 of 9
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size of 64 × 64 will be used. Trans-axial stress and rest
slices of 6 mm thickness will be reconstructed with a But-
terworth scattered back-projection filter, with a cuttoff fre-
quency of 0.4 Nyquist and an order of 6. Transaxial slices
will be reorientated to the cardiac axes for analysis. Data
will be processed using QGS software (Cedars-Sinai Med-
ical Center, USA) to calculate end diastolic and end systo-
lic volumes and wall motion scores. QPS (Cedars-Sinai
Medical Center, USA) will be used to for semiquantitative
analysis of the perfusion data including summed stress
and rest scores. The stress imaging protocol will be per-
formed using intravenous adenosine (140 mcg/kg/min)
for 4 minutes followed by isotope injection so that the
perfusion techniques of SPECT and CMR are directly com-
parable.
X-ray Angiography
All patients in this study will undergo invasive X-ray coro-
nary angiography by a cardiologist who will be blinded to
SPECT and CMR results. Patient management decisions
will be made independently of study participation. The
results of CMR will not be routinely available to clini-
cians. The SPECT results will be made available at the
request of the patient's clinician if SPECT was selected as
part of the planned investigations had the patient not par-
ticipated in the trial. Where the SPECT study is performed
for study purposes only (and not part of the initial clinical
diagnostic pathway) the results may be made available by
specific request following the coronary angiogram, to
guide patient management for example with regard to
identification of inducible ischaemia.
Investigation Reporting
All test results will be reported by independent clinical
and/or research staff, who will be blind to the results of all
other investigations.
CMR data sets will be simultaneously analysed by two car-
diologists with extensive experience in CMR and the fol-
lowing details will be recorded by consensus:
• Evidence of ischaemia by visual comparison of rest/
stress CMR perfusion scans (16 segments of the 17-
segment American Heart Association (AHA)/Ameri-
can College of Cardiology (ACC) model, excluding the
apical segment). A score of 0 (normal), 1 (equivocal),
2 (subendocardial ischaemia) or 3 (transmural ischae-
mia) will be assigned to each segment.
CE-MARC cardiac magnetic resonance protocolFigure 2
CE-MARC cardiac magnetic resonance protocol. The protocol commences with a low-resolution survey scan and local-
isers. Intravenous adenosine is then administered for approximately 4 minutes at 140 mcg/kg/min, following which first pass 
stress perfusion imaging is undertaken after the injection of 0.05 mmol/kg dimeglumine gadopentetate. Three dimensional 
whole heart MR coronary angiography follows the low resolution coronary survey and free-breathing 4 chamber cine (used to 
assess slice coverage and diastolic coronary rest period respectively). Rest perfusion imaging is undertaken a minimum of 15 
minutes following stress perfusion, with a further injection of 0.05 mmol/kg dimeglumine gadopentetate. A final injection of 0.1 
mmol/kg dimeglumine gadopentetate is given following this sequence, bringing the overall gadolinium dose to 0.2 mmol/kg. 
Resting left ventricular function is then assessed, initially for three slices planned identically to the perfusion slices, and then for 
the entire left ventricle using contiguous slices. A modified Look-Locker inversion time scout is performed prior to late gado-
linium enhancement imaging in short axis, vertical long axis and horizontal long axis orientations. Times indicated on the dia-
gram are approximate and sequence blocks are not drawn to scale.Page 5 of 9
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onary artery stenosis on the coronary MR angiogram
(17 coronary sections).
• Evidence of scar tissue (17 myocardial segment
model). A score of 0 (none), 1 (1–25%), 2 (26–50%),
3 (51–75%) or 4 (>75%) will be allocated to each seg-
ment.
• Evidence of regional wall motion abnormalities (17
myocardial segment model). Segmental wall motion
will be scored as 0 (normal), 1 (mild hypokinesia), 2
(severe hypokinesia), 3 (akinesia) or 4 (dyskinesia).
• Quantitative analysis will include: end systolic vol-
ume (ml), end diastolic volume (ml), ejection fraction
(%), left ventricular mass (g), scar tissue mass (g).
The quality of each CMR component will be graded on a
scale from 1 (poor) to 4 (excellent). A combined CMR
report based all CMR data will report whether the patient
has any evidence for CHD and whether this is functionally
significant as per the study definition. The affected myo-
cardial territories will be specified. Other cardiac and ext-
racardiac abnormalities will be noted.
Nuclear data sets will be analysed simultaneously by a car-
diologist (CD) with extensive experience in nuclear cardi-
ology and an experienced medical physicist. The
following details will be recorded by consensus:
• Evidence of ischaemia by visual comparison of rest/
stress SPECT perfusion scans (based on the standard
17-segment AHA/ACC model. A score of 0 (normal),
1 (equivocal), 2 (moderately reduced), 3 (severely
reduced) or 4 (absent) will be assigned to each seg-
ment.
• Evidence of ischaemia by semi-quantitatively scoring
using the QPS 20 segment, 5 point model (0 = normal,
1 = mildly reduced uptake, 2 = moderately reduced
uptake, 3 = severely reduced uptake and 4 = Absent
uptake). Summed stress and rest scores will be based
on the 20 segment model.
• Evidence of regional wall motion abnormalities (17
myocardial segment model). Segmental wall motion
will be scored as 0 (normal), 1 (mild hypokinesia), 2
(severe hypokinesia), 3 (akinesia) or 4 (dyskinesia).
• Quantitative analysis will include end systolic vol-
ume (ml), end diastolic volume (ml), ejection fraction
(%).
As for CMR, the study quality will be reported and a sum-
mary SPECT report will be produced with an assessment
of whether the patient and which vascular territory shows
evidence for CHD and whether this is functionally signif-
icant as per the study definition.
X-ray angiography images will be analysed by two cardiol-
ogists (JY and NM) with experience in invasive coronary
angiography. Quantitative coronary angiography (QCA)
analysis will be performed off-line using QCAPlus soft-
ware (Sanders Data Systems, Palo Alto, California, USA)
and the following details will be recorded:
 Coronary artery dominance
 Location and percentage of stenosis by visual estima-
tion and by QCA in each of the main coronary arteries
 Vessel diameter
 Ventricular function if assessed by left ventriculogra-
phy
ETT will be reported by the requesting clinician according
to the criteria of the ACC/AHA guidelines for exercise test-
ing [21], and the results collected including all the ETT
data specified above. In addition the clinician's opinion
on the ECG result (positive, borderline positive negative,
or equivocal for ischaemia) will be recorded.
Annual follow-up
Annual follow-up over the subsequent 3 years will be
undertaken. A number of procedural safeguards will be
followed to establish survival prior to a follow-up tele-
phone call. Information to be obtained at the telephone
consultation includes, medical history since randomisa-
tion including details and dates of; acute coronary syn-
drome, emergency or elective revascularisation procedure,
any admission for cardiovascular cause including heart
failure, cardiac arrhythmia, suspected cardiac event, acute
CHD hospitalisation, stroke/transient ischaemic attack
(cerebrovascular). These data will be verified from hospi-
tal or family practitioner records. Details of any recent car-
diovascular investigations will be taken. In addition,
Office of National Statistics (ONS) monitoring will be
sought for deceased patients to determine the certified
causes of death. Notification of deaths by ONS is inde-
pendent of the patients' clinical follow-up (if they remain
resident in the United Kingdom) and ensures recording of
unbiased cause-specific mortality both during the study
and after, for an indefinite period.
Definition of outcomes/events
Diagnosis of CHD
Significant CHD will be defined as ≥ 70% stenosis of a
first order coronary artery measuring ≥ 2 mm in diameter
at X-ray coronary angiography, or left main stem stenosis
≥50%.Page 6 of 9
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To assess the prognostic value of CMR, patients will be fol-
lowed for three years from test completion for the occur-
rence of a major adverse coronary event (MACE) which
will be a composite endpoint comprising at least one of
the following; death from cardiovascular cause, acute cor-
onary syndrome (with clinical and biomarker evidence),
late revascularisation (>3 months after the initial coronary
angiogram) and hospital admission for any cardiovascu-
lar cause.
Statistical considerations
Sample size
For our primary objective, estimating the diagnostic accu-
racy of CMR against the reference standard of X-ray angi-
ography we calculated that a sample size of 750 patients
would enable us to estimate the sensitivity or specificity of
CMR to within +/-3.5%. This assumes a sensitivity (or spe-
cificity) of 90% for CMR and 60% prevalence of signifi-
cant CHD in the study population and is based on the
precision of the 95% confidence interval for a proportion.
For the secondary objectives of comparing the diagnostic
accuracy of CMR with SPECT and also ETT, this number
would be sufficient to detect a 6.5% difference in sensitiv-
ities (or specificities) between CMR and SPECT with 80%
power, assuming a sensitivity of 85% for SPECT and 2-
sided analyses at the 5% significance level [22]. As the sen-
sitivity and specificity of ETT is expected to be lower at
around 68% sensitivity and 77% specificity, our sample
size will provide sufficient power to detect the expected
larger differences between CMR and ETT.
To assess the prognostic value of CMR in predicting MACE
approximately 10 events are required for each prognostic
factor in the statistical model [23]. The prognostic value of
the combined CMR conclusion will be assessed after
adjusting for the known risk factors age, gender, choles-
terol, blood pressure, smoking and diabetes, which would
require 70 events. It is estimated that approximately 30%
of patients will undergo planned revascularisation based
on the angiogram result and for this to be carried out usu-
ally within 8 weeks. For the remaining patients we esti-
mate that for every 70 patients, 10 will be normal with an
event rate of <1% per year and 60 will have CHD (30 sig-
nificant and 30 mild) with an event rate of approximately
5% per year. The required sample size of 750 patients for
the diagnostic accuracy evaluation would therefore result
in approximately 23 patients experiencing an event per
year. With a minimum follow-up period of 3 years this
would provide the required number of 70 patients with an
event.
Analysis plan
Analysis of the primary objective will be completed when
every patient has completed all of the diagnostic tests. All
statistical testing will be performed at a 2-sided 5% signif-
icance level. A final statistical analysis plan will be written
and reviewed before any statistical analysis is undertaken.
Analysis populations
The analysis population for the primary objective will
include all patients who have results for both CMR and X-
ray angiography. The analysis populations for the second-
ary objectives will include all patients who have the
appropriate data for each comparison. Patients withdraw-
ing from three year follow-up will be censored at the time
of withdrawal.
Missing data
The numbers of patients with missing data for one or
more tests, and the numbers of uninterpretable tests will
be reported. Patients with missing data for one or more
diagnostic tests will be excluded from any comparisons
involving those tests.
Test conduct
The numbers of patients undergoing each test will be
reported along with reasons why the test was not per-
formed, where available. The duration between the CMR
and X-ray angiography and also between the SPECT and
X-ray angiography will be summarised. Details of the
order of the testing sequences for each patient will also be
summarised.
Primary objective
Diagnostic accuracy – CMR compared to angiography
The sensitivity, specificity, positive and negative predictive
values and corresponding 95% confidence intervals for
the diagnostic performance of CMR in detecting the pres-
ence of significant CHD as confirmed by the X-ray angi-
ogram will be calculated. This will evaluate the combined
CMR conclusion. Additional analyses will also be per-
formed to explore the diagnostic accuracy of the individ-
ual CMR components: late enhancement, perfusion,
contractile function and CMR coronary angiography.
These components will be examined alone and in combi-
nation (with a positive result for CHD on one or more
tests being taken as a positive overall) to identify which
component of the CMR data has the best ability to detect
CHD.
Secondary objectives
Comparison of CMR with SPECT and ETT
The sensitivity, specificity, positive and negative predictive
values and corresponding 95% confidence intervals for
the diagnostic performance of SPECT and ETT compared
with the X-ray angiogram will be calculated. For the com-
parison of CMR with SPECT and also with ETT we will use
McNemar's test to compare the sensitivities and specifici-
ties.Page 7 of 9
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The prognostic ability of the combined CMR result alone
and after adjusting for the risk factors: age, gender, choles-
terol, blood pressure, smoking and diabetes in predicting
time to the first major cardiovascular event will be
assessed using Cox proportional hazards modelling.
Patients not experiencing an event will be treated as cen-
sored at their last known follow-up assessment. Hazard
ratios and 95% CI will be reported and Kaplan-Meier
curves will be calculated. This analysis will be for all
patients. Allowing physicians access to SPECT results is
ethically unavoidable but may also influence revasculari-
sation decisions and thus introduce an analysis bias. In
order to account for any possible bias and any differences
in the risk of future events resulting from decisions about
revascularization we will conduct additional analyses
which will adjust for the impact of revascularization on
outcomes by treating it as an intermediate event, using
time-dependent covariates and multistate models[24].
Adverse events
All serious adverse events that occur as a result of the diag-
nostic tests will be reported by diagnostic test. No formal
statistical testing will be undertaken.
Cost effectiveness
The cost-effectiveness of alternative diagnostic strategies
will be evaluated using data from CEMARC and published
sources. This will take the form of a decision analytic
model, which will provide a framework to link CEMARC
data on the diagnostic accuracy of the alternative forms of
diagnosis, information on therapeutic implications and
evidence on the ultimate costs to the UK National Health
Service and health benefits to patients in the form of qual-
ity-adjusted life-years (QALYs) [25]. In addition to infor-
mation on diagnostic accuracy, CEMARC will provide
data on clinicians' therapeutic plans following diagnostic
information provided by the alternative diagnostic
modalities. CEMARC will also provide data on the costs of
diagnostic tests. Using evidence from relevant systematic
reviews, the effects and costs of those therapies for a given
type of patient will be estimated and incorporated into the
model. The cost-effectiveness of alternative diagnostic
strategies will, therefore, be determined by the extent to
which the information they provide results into cost-effec-
tive changes in treatments. Modelling methods to reflect
long-term implications of changes in therapy for QALYs
and costs will reflect recent models published in the cardi-
ovascular area [26-28]
The general methods used will follow those defined as
good practice by the National Institute for Health and
Clinical Excellence (NICE) [29]. This will include model-
ling the full range of diagnostic strategies which would be
considered in the National Health Service (NHS), using
systematically identified estimates for all input parame-
ters, the use of probabilistic sensitivity analysis to express
the uncertainty in all elements of evidence in terms of the
probability that each diagnostic strategy is the most cost-
effectiveness and further scenario analysis to explore the
implications of key assumptions made in the model. We
will also use value of information analysis to assess where
future research in this area is likely to be the most valuable
[25].
Data monitoring
Data will be monitored for completeness and quality by
the CTRU. A full monitoring schedule, including Serious
Adverse Events and Adverse Reactions, will be established
and agreed by the Programme Steering Committee (PSC)
and Study Management Group (SMG).
Discussion
The CE-MARC study is a prospective, diagnostic accuracy
cohort study in a population of 750 out-patients present-
ing with chest pain. It aims to assess the diagnostic accu-
racy, for detection of significant CHD, using a multi-
parametric CMR protocol versus X-ray coronary angiogra-
phy, nuclear scintigraphy (SPECT) and exercise tolerance
testing (where feasible). The prognostic value of CMR and
its cost effectiveness will also be compared with these
modalities. CE-MARC will be the largest prospective trial
to date to compare CMR against standard non-invasive
investigations for the diagnosis of CHD, and may have
important implications for the wider adoption of CMR in
the future.
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